ReviewNature reviews. Rheumatology2023
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.
Review in Nature reviews. Rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Is sarcopenia a real concern in ankylosing spondylitis? A systematic literature review.European geriatric medicine · 2024Pooled it
- Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study.Rheumatology international · 2026Article
- How Organ Manifestations Beyond the Bone May Guide Risk Stratification and Treatment Decisions in Chronic Nonbacterial Osteomyelitis.Paediatric drugs · 2026Review
- Review
- Inflammatory Bowel Disease-Associated Spondyloarthritis.Journal of clinical medicine · 2026Review
- In Vivo Microendoscopy in the Near-Infrared II Window.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.EULAR rheumatology open · 2026Article
- Case Report: Dupilumab-associated ulcerative colitis: elucidating the pathomechanistic link between Th2 blockade and Th17 polarized intestinal inflammation.Frontiers in immunology · 2026Article
- Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study.Journal of gastroenterology · 2026Article
- Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance.Military Medical Research · 2026Review
- Body composition, bone mineral density, and functional impairment in axial spondyloarthritis: a 36-month longitudinal study.BMC musculoskeletal disorders · 2025Article
- Musculoskeletal Symptoms and Clinical Findings in Bio-naïve Patients with Inflammatory Bowel Disease Prior to Biological Treatment Initiation: A Prospective Cohort Study.Digestive diseases and sciences · 2025Article
- Nutritional guidance in spondyloarthritis: confronting the evidence gap.Current opinion in rheumatology · 2025Review
- Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Refractory psoriatic arthritis: emerging concepts in whole process management.Clinical rheumatology · 2025Review
- Characteristics and multi-omics analysis of spontaneous spondyloarthritis in non-human primates: Case report.Heliyon · 2025Article
- Successful treatment of Crohn's disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review.Rheumatology international · 2024Review
- The shared role of neutrophils in ankylosing spondylitis and ulcerative colitis.Genes and immunity · 2024Article
- Strategies for targeting cytokines in inflammatory bowel disease.Nature reviews. Immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory diseases that can affect both axial and peripheral joints, tendons and entheses. Among the extra-articular manifestations, inflammatory bowel disease (IBD) is associated with considerable morbidity and effects on quality of life. In everyday clinical practice, treatment of these conditions requires a close collaboration between gastroenterologists and rheumatologists to enable early detection of joint and intestinal manifestations during follow-up and to choose the most effective therapeutic regimen, implementing precision medicine for each patient's subtype of SpA and IBD. The biggest issue in this field is the dearth of drugs that are approved for both diseases, as only TNF inhibitors are currently approved for the treatment of full-spectrum SpA-IBD. Janus tyrosine kinase inhibitors are among the most promising drugs for the treatment of peripheral and axial SpA, as well as for intestinal manifestations. Other therapies such as inhibitors of IL-23 and IL-17, phosphodiesterase 4 inhibitor, α4β7 integrin blockers and faecal microbiota transplantation seem to only be able to control some disease domains, or require further studies. Given the growing interest in the development of novel drugs to treat both conditions, it is important to understand the current state of the art and the unmet needs in the management of SpA-IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.